Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRONTiER: Nivolumab with Neoadjuvant CF or DCF for Esophageal Carcinoma
NCT03914443Phase 1Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2019
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Rate of participants with dose limiting toxicities. Started May 2019; status: completed.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03914443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03914443.